Chronic treatment with aripiprazole prevents development of dopamine supersensitivity and potentially supersensitivity psychosis

Schizophrenia Bulletin

Volumn 38, Issue 5, 2012, Pages 1012-1020

  Tadokoro, Shigenori ^a   Okamura, Naoe ^b   Sekine, Yoshimoto ^b   Kanahara, Nobuhisa ^a   Hashimoto, Kenji ^b   Iyo, Masaomi ^a,b  

^a CHIBA UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

^b CHIBA UNIVERSITY   (Japan)

Author keywords

D2 dopamine receptor; locomotor activity; partial agonist; radioligand binding assay; rat; striatum

Indexed keywords

ARIPIPRAZOLE; DOPAMINE; DOPAMINE 2 RECEPTOR; HALOPERIDOL; METHAMPHETAMINE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BEHAVIOR; LOCOMOTION; LONG TERM EXPOSURE; MALE; MINIPUMP; NONHUMAN; PRIORITY JOURNAL; PSYCHOSIS; RAT; RECEPTOR BINDING; RECEPTOR DENSITY; SUPERSENSITIVITY; THERAPY EFFECT;

ANIMALS; ANTIPSYCHOTIC AGENTS; CORPUS STRIATUM; DOPAMINE UPTAKE INHIBITORS; HALOPERIDOL; LONG-TERM CARE; MALE; METHAMPHETAMINE; MOTOR ACTIVITY; PIPERAZINES; PSYCHOSES, SUBSTANCE-INDUCED; QUINOLONES; RADIOLIGAND ASSAY; RATS; RATS, SPRAGUE-DAWLEY; RECEPTORS, DOPAMINE D2; SCHIZOPHRENIA;

EID: 84857523173     PISSN: 05867614     EISSN: 17451701     Source Type: Journal    
DOI: 10.1093/schbul/sbr006     Document Type: Article

References (32)

1. Snyder SH. Dopamine receptors, neuroleptics, and schizophrenia. Am J Psychiatry. 1981;138:460-464.
2. Kane JM. Treatment strategies to prevent relapse and encourage remission. J Clin Psychiatry. 2007;68(suppl 14):27-30.
3. Weiden P, Rapkin B, Zygmunt A, Mott T, Goldman D, Frances A. Postdischarge medication compliance of inpatients converted from an oral to a depot neuroleptic regimen. Psychiatr Serv. 1995;46:1049-1054.
4. Carpenter WT, McGlashan TH, Strauss JS. The treatment of acute schizophrenia without drugs: an investigation of some current assumptions. Am J Psychiatry. 1977;134(1):14-20.
5. Davis KL, Rosenberg GS. Is there a limbic system equivalent of tardive dyskinesia? Biol Psychiatry. 1979;14:699-703.
6. Chouinard G, Jones BD, Annable L. Neuroleptic-induced supersensitivity psychosis. Am J Psychiatry. 1978;135:1409-1410.
7. Chouinard G, Jones BD. Neuroleptic-induced supersensitivity psychosis: clinical and pharmacologic characteristics. Am J Psychiatry. 1980;137(1):16-21.
8. Chouinard G, Creese I, Boisvert D, Annable L, Bradwejn J, Jones B. High neuroleptic plasma levels in patients manifesting supersensitivity psychosis. Biol Psychiatry. 1982;17: 849-852.
9. Chouinard G. Severe cases of neuroleptic-induced supersensitivity psychosis. Diagnostic criteria for the disorder and its treatment. Schizophr Res. 1991;5(1):21-33.
10. Kirkpatrick B, Alphs L, Buchanan RW. The concept of supersensitivity psychosis. J Nerv Ment Dis. 1992;180:265-270.
11. Gorwood P. Meeting everyday challenges: antipsychotic therapy in the real world. Eur Neuropsychopharmacol. 2006;16(suppl 3):S156-S162.
12. Murugaiah K, Theodorou A, Mann S, Clow A, Jenner P, Marsden CD. Chronic continuous administration of neuroleptic drugs alters cerebral dopamine receptors and increases spontaneous dopaminergic action in the striatum. Nature. 1982;296:570-572.
13. Sasaki H, Hashimoto K, Inada T, Fukui S, Iyo M. Suppression of oro-facial movements by rolipram, a cAMP phosphodiesterase inhibitor, in rats chronically treated with haloperidol. Eur J Pharmacol. 1995;282(1-3):71-76.
14. Sasaki H, Hashimoto K, Maeda Y, et al. Rolipram, a selective c-AMP phosphodiesterase inhibitor suppresses oro-facial dyskinetic movements in rats. Life Sci. 1995;56:PL443-P447.
15. Seeman P, Schwarz J, Chen JF, et al. Psychosis pathways converge via D2high dopamine receptors. Synapse. 2006;60:319-346.
16. Samaha AN, Seeman P, Stewart J, Rajabi H, Kapur S. " Breakthrough" dopamine supersensitivity during ongoing antipsychotic treatment leads to treatment failure over time. J Neurosci. 2007;27:2979-2986.
17. Ohmori T, Miura S, Yamashita I, et al. Late phase II study of aripiprazole for schizophrenia. Jpn J Clin Psychopharmacol. 2006;9:271-293.
18. Asakura W, Matsumoto K, Ohta H, Watanabe H. REM sleep deprivation decreases apomorphine-induced stimulation of locomotor activity but not stereotyped behavior in mice. Gen Pharmacol. 1992;23:337-341.
19. Huang N, Ase AR, Hebert C, van Gelder NM, Reader TA. Effects of chronic neuroleptic treatments on dopamine D1 and D2 receptors: homogenate binding and autoradiographic studies. Neurochem Int. 1997;30:277-290.
20. Kapur S, VanderSpek SC, Brownlee BA, Nobrega JN. Antipsychotic dosing in preclinical models is often unrepresentative of the clinical condition: a suggested solution based on in vivo occupancy. J Pharmacol Exp Ther. 2003;305: 625-631.
21. Cheng YF, Paalzow LK. Linear pharmacokinetics of haloperidol in the rat. Biopharm Drug Dispos. 1992;13(1):69-76.
22. Bezchlibnyk-Butler KZ, Jeffries JJ. Clinical Handbook of Psychotropic Drugs. Toronto, ON: Hogrefe & Huber Publishers; 1999.
23. Shimokawa Y, Akiyama H, Kashiyama E, Koga T, Miyamoto G. High performance liquid chromatographic methods for the determination of aripiprazole with ultraviolet detection in rat plasma and brain: application to the pharmacokinetic study. J Chromatogr B Analyt Technol Biomed Life Sci. 2005;821(1):8-14.
24. Mauri MC, Volonteri LS, Colasanti A, Fiorentini A, De Gaspari IF, Bareggi SR. Clinical pharmacokinetics of atypical antipsychotics: a critical review of the relationship between plasma concentrations and clinical response. Clin Pharmacokinet. 2007;46:359-388.
25. Inoue A, Miki S, Seto M, et al. Aripiprazole, a novel antipsychotic drug, inhibits quinpirole-evoked GTPase activity but does not up-regulate dopamine D2 receptor following repeated treatment in the rat striatum. Eur J Pharmacol. 1997;321(1):105-111.
26. Tsai SJ. Dopamine receptor downregulation: an alternative strategy for schizophrenia treatment. Med Hypotheses. 2004;63:1047-1050.
27. Lawler CP, Prioleau C, Lewis MM, et al. Interactions of the novel antipsychotic aripiprazole (OPC-14597) with dopamine and serotonin receptor subtypes. Neuropsychopharmacology. 1999;20:612-627.
28. Shapiro DA, Renock S, Arrington E, et al. Aripiprazole, a novel atypical antipsychotic drug with a unique and robust pharmacology. Neuropsychopharmacology. 2003;28:1400-1411.
29. Urban JD, Vargas GA, von Zastrow M, Mailman RB. Aripiprazole has functionally selective actions at dopamine D2 receptor-mediated signaling pathways. Neuropsychopharmacology. 2007;32(1):67-77.
30. Burris KD, Molski TF, Xu C, et al. Aripiprazole, a novel antipsychotic, is a high-affinity partial agonist at human dopamine D2 receptors. J Pharmacol Exp Ther. 2002;302:381-389.
31. Chouinard G, Chouinard VA. Atypical antipsychotics: CATIE study, drug-induced movement disorder and resulting iatrogenic psychiatric-like symptoms, supersensitivity rebound psychosis and withdrawal discontinuation syndromes. Psychother Psychosom. 2008;77(2):69-77.
32. Di Lorenzo R, Amoretti A, Forghieri M, Fiorini F, Genedani S, Rigatelli M. Aripiprazole: effectiveness and safety under naturalistic conditions. Exp Clin Psychopharmacol. 2007;15:569-575.